



# MOREPEN

Date: 16/05/2018

To,

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
Tel No: (022) 26598100 - 8114  
Fax No: (022) 26598120  
Symbol: MOREPENLAB

**BSE Limited**  
Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001  
Phones: 91-22-22721233/4  
Fax: 91-22-2272 3121  
Scrip Code: 500288

**Subject: Intimation of Post Results (Q4 of FY 2017-18) Conference Call of Morepen Laboratories Limited**

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that subsequent to the declaration of Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018, the Company is organizing an 'Investor and Analyst Conference Call' on **Friday, 18<sup>th</sup> May, 2018 at 2.00 p.m. (IST)**.

The details of the conference call are attached herewith.

This is for your information and records.

Thanking you.

Yours faithfully,

**For Morepen Laboratories Limited**

**(Thomas P. Joshua)**  
Company Secretary

**Encl.: As Above**

## **Morepen Laboratories Limited**

**Corp. Off.:** 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA  
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com  
CIN NO. L24231 HP1984PLC006028

**Plant & Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205  
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com



**Morepen Laboratories Ltd** is one of India's leading API, Formulations & Health Care diagnostics manufacturer. The company will be hosting a conference call for investor and analyst community on **Friday, May 18<sup>th</sup>, 2018 at 2.00 pm IST**

The call will be initiated with a brief management discussion on the company, business segments and earnings performance followed by an interactive question and answer session.

On behalf of the company the call will addressed by:

- **Mr Sushil Suri: Chairman and Managing Director**
- **Mr Ajay Sharma: Chief Financial Officer**

**Details of the conference call are as follows:**

**Friday, 18<sup>th</sup> May 2018 - 2.00 pm IST**

<b>Mumbai (Primary No.)</b>	<b>+91 22- 6280 1239</b>
<b>Universal Access</b>	<b>022 7115 8140</b>
<b>USA</b>	<b>18667462133</b>
<b>UK</b>	<b>08081011573</b>
<b>Singapore</b>	<b>8001012045</b>
<b>Hong Kong</b>	<b>800964448</b>

**Note:** When using dial-in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time.

=====

Connect to your call without having to wait for an operator

Click on this URL or Copy this URL in your browser:

<http://services.choruscall.in/diamondpass/registration?confirmationNumber=5118872>

=====

**About Morepen Laboratories Ltd**

Morepen Laboratories Limited is a 33 old Rs. 600 crores pharmaceuticals and healthcare products company. The company went public in 1993 and is currently listed on both National Stock exchange and Bombay Stock Exchange.

Morepen is engaged in the manufacturing and sale of API/Bulk Drugs, Home Diagnostics, formulations, and OTC products. The company's state of the art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10 plants, each with a specific product profile. The USFDA plant at Masulkhana is for the manufacture of Loratadine, an anti – allergy drug – internationally known as Claritin. The new blockbuster drug Montelukast is also manufactured at this FDA approved site.

The large and spread out manufacturing facility at Baddi manufactures latest and much in demand products like Atorvastatin, Rosuvastatin, Sitagliptin and others for regulated markets of USA and also for non-regulated markets across the globe.

Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic markets. It has WHO GMP facilities for manufacturing of formulations. The company's manufacturing facilities are backed by a strong and dedicated team of research and development (R&D) professionals who ensure stringent quality standards. In home Diagnostics business, Morepen has a formidable presence in blood Glucose monitors and Blood pressure monitors in the domestic market. The company's OTC brands are being promoted under its wholly owned subsidiary Dr Morepen limited. Dr Morepen's famous OTC product line including Burnol, Lemolate, Sat-Isabgol, pain-X and others has a significant presence in domestic market.

The company's wholly owned subsidiary Dr Morepen Ltd is setting up a first of its kind chain of health care centers in India by the name of Dr Morepen Now to offer ECP Therapy to target consumers in India. The move is part of Company's "Nation on wellness (Now)" drive, which envisions providing non-invasive means to treat cardiovascular diseases and diseases associated with Cardio-metabolic issues gripping the country today.

[For any further information please contact](#)

Mr. Sonal Kumar Shrivastava  
Kirin Advisors Pvt Ltd  
Ph -9324748334  
Email: [sonalkumar@kirinadvisors.com](mailto:sonalkumar@kirinadvisors.com)

## **DISCLAIMER:**

*Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and abroad. Actual results might differ substantially from those expressed or implied. Morepen Laboratories Ltd and its Management will not be in any way responsible for any action taken based on such statements and discussions. Morepen also undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*